Refine by
Alzheimer Disease Articles & Analysis
140 news found
We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions. In 2024, we are focusing our efforts on two of our most promising programs: Hypoplastic Left Heart Syndrome (HLHS); and Alzheimer's ...
Emotion-related animal behavior tests aim to provide a good research tool for the study of emotion-associated diseases. Anxiety and depression affect millions of individuals worldwide, leading to a significant burden on public health and impacting overall quality of life. Depression is commonly seen in neurodegenerative and neurodevelopmental diseases such as ...
BOC Sciences managers and technicians also take pride in the contributions their USP impurity standards make to extensive disease research areas. Data collected by BOC Sciences reveal that drug researchers and manufacturers seek impurity material support in a variety of fields, including Alzheimer's disease, diabetes, anti-HBV, and anti-HCV. ...
Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with neurodegenerative diseases for potential disease modification. Under the terms of the agreement and pending regulatory clearance, Teva will receive an exclusive global license to develop, manufacture and commercialize anle138b and sery433. ...
Phase 1 trial of tau-targeting lead program planned to begin in 3Q22 Funding will also support the characterization of the Company’s second-generation assets Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,472,776 (the ‘776 patent) titled, “Novel Quinazolinones that Inhibit the Formation of Tau ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer's ...
Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases CY6463 favorable tolerability and safety profile was confirmed Ariana Pharma, a leading Artificial Intelligence (AI) drug development company, in collaboration with Cyclerion Therapeutics, presented today safety and ...
About Biogen As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners ...
About Biogen As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners ...
Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s Identified two lead cannabinoid analog compounds for in vivo studies NSERC grant funding supports InMed’s collaborative research projects with Dr. ...
The level of beta-amyloid removal, the protein that builds up to make plaques in the brains of people with Alzheimer's disease, was lower than expected. Gantenerumab was well tolerated, including the subcutaneous administration. ...
His vast experience and proven track record will greatly support Elucid’s continued work in combating cardiovascular disease,” said Blake Richards, chief executive officer, Elucid. ...
ByElucid
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that management will be presenting at the upcoming conferences: BioFuture Panel Title: New Diagnostics: Revolutionizing Care in Alzheimer’s Date/Time: Wednesday, Nov. 9, ...
The role of the immune system and inflammation in Alzheimer’s disease has been broadly known for years but it is becoming increasingly clear that effective management of AD may require anti-inflammatory strategies. ...
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study. Initial results were presented by Ariana Pharma at the Alzheimer’s Association International Conference ...
“We are extremely pleased to receive this R44 grant which will allow us to plan for a Phase 1b, doubleblind clinical study of OLX-07010 in patients with Alzheimer’s disease,” said William Erhardt, M.D., President and Head of Development at Oligomerix. ...
For more information, please visit http://www.flowonix.com About Cerebral Therapeutics Cerebral Therapeutics, LLC is a privately-held company founded with the goal of addressing the well-recognized limitations of existing treatments for uncontrolled neurological diseases. Cerebral Therapeutics is combining advanced micro-dosing technology with proprietary medications to ...
The 2022 RNAi Roundtable schedule is as follows: Cemdisiran, in Development for the Treatment of IgA Nephropathy (IgAN) and Other Complement-Mediated Diseases Tuesday, September 27, 10:00 am ET Alnylam Engine for Sustainable Innovation: Leadership in RNAi Platform and Human Genetics Friday, October 21, 10:00 am ET CNS Delivery and ALN-APP, in Development for the ...